How the Meticulous Researcher Validates Their Cell Counting Method

– 6 min read

Yes, Meticulous Researchers validate their cell counting method! It’s what qualifies them as being meticulous… Did you ever do it, though?

You can benefit a lot from validating your cell counting method. First and foremost, if you have confidence that your cell count is correct, you can trust your data and won’t lose sleep over at least THAT parameter of your setup and results.

The Meticulous Researchers know, and we created this cheat-sheet to see how they work.

1. They know the difference between accuracy and precision

These are the basics to be on top of in cell counting. If you want to validate the precision and accuracy of your own cell counting instrument, it is best done by validating the linearity of your cell count through a 1:1 dilution series and ensuring that your results are linear, i.e., that your R2 is close to 1.0.

Precise cell counting

2. They know their working range and linearity of viability

Linearity of viability

Meticulous Researchers have tested the outer boundaries of cell concentrations at which they can count cells in a linear range, i.e. count with confidence. They have also mixed living and dead cells at different known ratios and tested whether the instrument actually does identify the cells as living or dead.

3. They have tested the instrument-to-instrument variability

When using different cell counting instruments across the production and quality control processes, it is crucial that data validated at one point can be compared to data at a different process point, so you can get an overall picture of the production run and validate the performance. The Meticulous Researcher did this in their instrument validation through extensive replica testing. Boring, yes. But extremely satisfying when you just KNOW that your instruments are aligned.

4. They know their people’s strengths and weaknesses

Meticulous Researchers know whether one lab member counts differently from the other and whether this is due to sample handling, instrument operation or something else. They have tested it, they analyzed the data, they know. They just KNOW! Inter- and intra-operator variation can kill a production run.

5. They know their instrument’s strengths and weaknesses

The Meticulous Researcher also knows whether any contaminants of their cell culture production run potentially affects their cell counting method. Yes, of course they tested this as well – they test everything!

This image has an empty alt attribute; its file name is Instruments-Strengths-and-Weaknesses.jpg

Get the webinar on refining your cell counting method

Our Field Application Scientists (FAS) get questions from many of our customers on how to validate their cell counting method. Luckily, they know how the Meticulous Researcher does this. We hosted a webinar with a full guide, so you can follow the same methodology of the Meticulous Researcher: How Precise are Your Cell Counts? It’s not hard at all, it just takes time and dedication, and you will know all about how much you can trust your cell counter.

Further Reading

By Janny Marie L Peterslund, Scientific Affairs Manager at ChemoMetec
Janny Marie has a background in stem cell research at Novo Nordisk, Denmark. She worked at STEMCELL Technologies, supporting and managing the epithelial cell culture product portfolio. Now at ChemoMetec, Janny Marie supports collaborations with external partners and writes for the Cell Counting Blog. 

Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://chemometec.com/how-the-meticulous-researcher-validates-their-cell-counting-method/

Weiterlesen

Internationaler Tag der Biodiversität – Symrise engagiert sich

— Förderung nachhaltiger Biodiversitätsinitiativen auf globaler Ebene
— Verantwortungsvolle Beschaffung biologischer Ressourcen durch nachhaltige Rückwärtsintegration
— Biologische Vielfalt essenzielle Lebensgrundlage und Grundpfeiler für Duft, Geschmack, Ernährung und Pflege
— Ausbau der Vorreiterrolle im Schutz von Biodiversität und nachhaltiger Unternehmenstätigkeit Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.symrise.com/de/newsroom/artikel/internationaler-tag-der-biodiversitaet-symrise-engagiert-sich/

Weiterlesen

Evotec SE reports results for the first quarter 2021 and provides corporate update

Evotec SE today announced the financial results and corporate updates for the first quarter 2021. Group revenues from contracts with customers increased by 11% to € 133.1 m (Q1 2020: € 119.4 m); Base business growth of 28%, adjusted for the end of the Sanofi payment (since April 2020) and unfavourable fx effects; EVT Execute revenue growth of 16% (11% adjusted for material recharges) to € 136.9 m (Q1 2020: € 118.2 m), EVT Innovate revenues up 21% (20% adjusted for material recharges) to € 28.2 m (Q1 2020: € 23.3 m) Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-se-reports-results-for-the-first-quarter-2021-and-provides-corporate-update-6066

Weiterlesen

Symrise unterzeichnet revolvierende Kreditlinie mit Nachhaltigkeitskomponente in Höhe von 500 Mio. €

— Revolvierende Kreditlinie ersetzt bestehende in Höhe von 300 Mio. € — Zinsmarge ist an drei Nachhaltigkeits-Kennzahlen zu Treibhausgas-Emissionen, Rohstoffbeschaffung und Wasserverbrauch gekoppelt
— Nachhaltigkeitsgebundene Anpassungen der Zinsmarge zugunsten von Projekten der Hilfsorganisation „Save the Children“ in Madagaskar Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.symrise.com/de/newsroom/artikel/symrise-unterzeichnet-revolvierende-kreditlinie-mit-nachhaltigkeitskomponente-in-hoehe-von-500-mio-EUR/

Weiterlesen

Evotec launches "beLAB1407" to accelerate translational research from the UK's academic life science ecosystem in collaboration with Bristol Myers Squibb

Evotec SE announced today that the Company, together with Bristol-Myers Squibb Company (NYSE: BMY), has launched beLAB1407, a new $ 20 m academic BRIDGE to identify and advance novel and breakthrough drug discovery opportunities across therapeutic areas from the UK’s top-tier academic institutions. Through a unique combination of Evotec’s drug discovery and development platforms and early-stage therapeutic concepts from the Universities of Birmingham, Edinburgh, Nottingham, and Dundee, beLAB1407 offers a unique route to the advancement of first-in-class therapeutics and the creation of spin-out companies. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-launches-belab1407-to-accelerate-translational-research-from-the-uks-academic-life-science-ecosystem-in-collaboration-with-bristol-myers-squibb-6064

Weiterlesen

Evotec and the GCKD study enter into strategic collaboration to build a unique molecular patient database

Evotec SE and the University Hospital Erlangen today announced a partnership regarding molecular analyses of biospecimens from the German Chronic Kidney Disease (“GCKD”) cohort study. Under the agreement, the research team will make use of Evotec’s proprietary EVOpanOmics and EVOpanHunter platforms to facilitate deep molecular profiling of patient samples. The Evotec platforms combine enhanced throughput proteomics, high-throughput transcriptomics and integrated data analysis.  Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-the-gckd-study-enter-into-strategic-collaboration-to-build-a-unique-molecular-patient-database-6059

Weiterlesen

Evotec SE to announce results for the first quarter 2021 on 11 May 2021

Evotec SE will announce its financial results for the first quarter of 2021 on Tuesday, 11 May 2021. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. The conference call will be held in English. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-se-to-announce-results-for-the-first-quarter-2021-on-11-may-2021-6061

Weiterlesen

Bristol Myers Squibb exercises option to extend targeted protein degradation partnership with Evotec

Evotec SE today announced that Bristol Myers Squibb has decided to exercise their option to extend its partnership with Evotec in the field of targeted protein degradation. Evotec and Bristol Myers Squibb (the successor in interest to Celgene) initiated this strategic drug discovery and development partnership in 2018 with the goal to identify first-in-class drug candidates initially focusing on solid tumours. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/bristol-myers-squibb-exercises-option-to-extend-targeted-protein-degradation-partnership-with-evotec-6057

Weiterlesen

Chairman of the Supervisory Board of Evotec to resign from office effective as of the end of the Annual General Meeting on 15 June 2021

Evotec SE announces that today the Chairman of the Supervisory Board, Prof. Dr Wolfgang Plischke, has informed the Company of his decision to resign from his office in the Supervisory Board of Evotec SE effective as of the end of the Annual General Meeting on 15 June 2021 due to personal reasons. Prof. Dr Plischke has been serving in the Supervisory Board as Chairman since 2014. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/ad-hoc-releases/p/chairman-of-the-supervisory-board-of-evotec-to-resign-from-office-effective-as-of-the-end-of-the-annual-general-meeting-on-15-june-2021-6055

Weiterlesen